

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93797

Yuji HOYANO, et al.

Appln. No.: 10/572,515

Group Art Unit: 4161

Confirmation No.: 4754

Examiner: Bong-Sook Baek

Filed: March 17, 2006

For: CONCURRENT DRUGS

RESPONSE TO ELECTIONS/RESTRICTIONS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to Election/Restrictions dated April 10, 2008, twice extended to July 10, 2008 by an appropriate two month petition extension of time and fee submitted herewith, applicants elect the claims of Group I, claims 1-2, and 4 drawn to a composition comprising an anti-platelet agent and a 5-amidino-2-hydroxybenzenesulfonamide derivative. Election is without traverse.

With respect to Species Elections, the Examiner poses this as follows:

If applicant selects Group I or II, one species from 5-amidino-2-hydroxybenzene-sulfonamide derivative set forth in claim 1, 4, and 12 and one species from anti-platelet agents (aspirin, dipyridamole, cilostazol, ticlopidine and clopidogrel) set forth in claim 2 and 11 should be chosen to be fully responsive.


RESPONSE TO ELECTIONS/RESTRICTIONS
U.S. Application No.: 10/572,515

Attorney Docket No.: Q93797

In response, Applicants elect [4-[2-(5-amidino-2-hydroxybenzenesulfonylamino)ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetic acid set forth in claim 4 from the 5-amidino-2-hydroxybenzenesulfonamide derivatives, and elect cilostazol set forth in claim 2 from the anti-platelet agents, as each single species in the elected claims.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 26, 2008